Biological interplay between proteoglycans and their innate immune receptors in inflammation

FEBS Journal

Volumn 280, Issue 10, 2013, Pages 2165-2179

  Frey, Helena ^a   Schroeder, Nina ^a   Manon Jensen, Tina ^a   Iozzo, Renato V ^b   Schaefer, Liliana ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

biglycan; decorin; hyaluronan; lumican; versican

Indexed keywords

BIGLYCAN; DECORIN; GLYCOSAMINOGLYCAN; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 1BETA; LEUCINE; LUMICAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEOGLYCAN; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X7 RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; VERSICAN;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MOLECULAR INTERACTION; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BIGLYCAN; CHONDROITIN SULFATE PROTEOGLYCANS; DECORIN; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-1BETA; KERATAN SULFATE; MICE; PROTEOGLYCANS; RECEPTOR CROSS-TALK; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; SOLUBILITY; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84877703267     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12145     Document Type: Review

References (156)

1. Chen GY, &, Nunez G, (2010) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10, 826-837.
2. Piccinini AM, &, Midwood KS, (2010) DAMPening inflammation by modulating TLR signalling. Mediators Inflamm, doi: 10.1155/2010/672395.
3. Tang D, Kang R, Coyne CB, Zeh HJ, &, Lotze MT, (2012) PAMPs and DAMPs: signals that spur autophagy and immunity. Immunol Rev 249, 158-175.
4. Trinchieri G, (2012) Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol 30, 677-706.
5. Schaefer L, &, Iozzo RV, (2012) Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev 22, 56-57.
6. Goh FG, &, Midwood KS, (2012) Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology (Oxford) 51, 7-23.
7. Takeuchi O, &, Akira S, (2010) Pattern recognition receptors and inflammation. Cell 140, 805-820.
8. Lundberg AM, &, Yan ZQ, (2011) Innate immune recognition receptors and damage-associated molecular patterns in plaque inflammation. Curr Opin Lipidol 22, 343-349.
9. Newton K, &, Dixit VM, (2012) Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol, doi: 10.1101/cshperspect.a006049.
10. Erridge C, (2010) Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 87, 989-999.
11. Jin MS, &, Lee JO, (2008) Structures of the toll-like receptor family and its ligand complexes. Immunity 29, 182-191.
12. Akashi-Takamura S, &, Miyake K, (2008) TLR accessory molecules. Curr Opin Immunol 20, 420-425.
13. Chun KH, &, Seong SY, (2010) CD14 but not MD2 transmit signals from DAMP. Int Immunopharmacol 10, 98-106.
14. Ospelt C, &, Gay S, (2010) TLRs and chronic inflammation. Int J Biochem Cell Biol 42, 495-505.
15. Gross O, Thomas CJ, Guarda G, &, Tschopp J, (2011) The inflammasome: an integrated view. Immunol Rev 243, 136-151.
16. Allam R, Scherbaum CR, Darisipudi MN, Mulay SR, Hagele H, Lichtnekert J, Hagemann JH, Rupanagudi KV, Ryu M, Schwarzenberger C, et al,. (2012) Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc Nephrol 23, 1375-1388.
17. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Gotte M, et al,. (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115, 2223-2233. (Pubitemid 41134165)
18. Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhao JG, Lemarchand P, Pfeilschifter J, Schaefer RM, Iozzo RV, et al,. (2011) Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal 4, ra75.
19. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, &, Karin M, (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102-106.
20. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, &, Simon JC, (2002) Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195, 99-111. (Pubitemid 34074500)
21. Noble PW, McKee CM, Cowman M, &, Shin HS, (1996) Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J Exp Med 183, 2373-2378. (Pubitemid 26158930)
22. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, et al,. (2009) Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15, 774-780.
23. Johnson GB, Brunn GJ, Kodaira Y, &, Platt JL, (2002) Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 168, 5233-5239. (Pubitemid 34495991)
24. Schaefer L, (2010) Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr Opin Pharmacol 10, 185-190.
25. Moreth K, Iozzo RV, &, Schaefer L, (2012) Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle 11, 2084-2091.
26. Sorokin L, (2010) The impact of the extracellular matrix on inflammation. Nat Rev Immunol 10, 712-723.
27. Iozzo RV, (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67, 609-652. (Pubitemid 28411140)
28. Schaefer L, &, Schaefer RM, (2010) Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res 339, 237-246.
29. Schaefer L, (2012) Introduction to proteoglycans: structure, pathobiology and signaling. In Extracellular Matrix: Pathobiology and Signaling (, Karamanos NK, ed.), pp. 135-140. Walter de Gruyter, Berlin/Boston.
30. McDonald J, &, Hascall VC, (2002) Hyaluronan minireview series. J Biol Chem 277, 4575-4579. (Pubitemid 34968481)
31. Lee JY, &, Spicer AP, (2000) Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 12, 581-586.
32. Itano N, (2008) Simple primary structure, complex turnover regulation and multiple roles of hyaluronan. J Biochem 144, 131-137.
33. Bianco P, Fisher LW, Young MF, Termine JD, &, Robey PG, (1990) Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J Histochem Cytochem 38, 1549-1563. (Pubitemid 20346965)
34. Choi HU, Johnson TL, Pal S, Tang LH, Rosenberg L, &, Neame PJ, (1989) Characterization of the dermatan sulfate proteoglycans, DS-PGI and DS-PGII, from bovine articular cartilage and skin isolated by octyl-sepharose chromatography. J Biol Chem 264, 2876-2884. (Pubitemid 19057783)
35. McBride OW, Fisher LW, &, Young MF, (1990) Localization of PGI (biglycan, BGN) and PGII (decorin, DCN, PG-40) genes on human chromosomes Xq13-qter and 12q, respectively. Genomics 6, 219-225. (Pubitemid 20164189)
36. Fisher LW, Termine JD, &, Young MF, (1989) Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J Biol Chem 264, 4571-4576. (Pubitemid 19081361)
37. Fisher LW, Termine JD, Dejter SW Jr, Whitson SW, Yanagishita M, Kimura JH, Hascall VC, Kleinman HK, Hassell JR, &, Nilsson B, (1983) Proteoglycans of developing bone. J Biol Chem 258, 6588-6594. (Pubitemid 13106831)
38. Johnstone B, Markopoulos M, Neame P, &, Caterson B, (1993) Identification and characterization of glycanated and non-glycanated forms of biglycan and decorin in the human intervertebral disc. Biochem J 292, 661-666. (Pubitemid 23210192)
39. Roughley PJ, White RJ, Magny MC, Liu J, Pearce RH, &, Mort JS, (1993) Non-proteoglycan forms of biglycan increase with age in human articular cartilage. Biochem J 295, 421-426. (Pubitemid 23315180)
40. Schonherr E, Witsch-Prehm P, Harrach B, Robenek H, Rauterberg J, &, Kresse H, (1995) Interaction of biglycan with type I collagen. J Biol Chem 270, 2776-2783.
41. Hunzelmann N, Anders S, Sollberg S, Schonherr E, &, Krieg T, (1996) Co-ordinate induction of collagen type I and biglycan expression in keloids. Br J Dermatol 135, 394-399. (Pubitemid 26297834)
42. Reinboth B, Hanssen E, Cleary EG, &, Gibson MA, (2002) Molecular interactions of biglycan and decorin with elastic fiber components: biglycan forms a ternary complex with tropoelastin and microfibril-associated glycoprotein 1. J Biol Chem 277, 3950-3957. (Pubitemid 34968648)
43. Douglas T, Heinemann S, Bierbaum S, Scharnweber D, &, Worch H, (2006) Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan. Biomacromolecules 7, 2388-2393. (Pubitemid 44336350)
44. Hwang JY, Johnson PY, Braun KR, Hinek A, Fischer JW, O'Brien KD, Starcher B, Clowes AW, Merrilees MJ, &, Wight TN, (2008) Retrovirally mediated overexpression of glycosaminoglycan-deficient biglycan in arterial smooth muscle cells induces tropoelastin synthesis and elastic fiber formation in vitro and in neointimae after vascular injury. Am J Pathol 173, 1919-1928.
45. Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR, Border WA, &, Ruoslahti E, (1994) Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 302, 527-534. (Pubitemid 24280108)
46. Tufvesson E, &, Westergren-Thorsson G, (2002) Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS Lett 530, 124-128. (Pubitemid 35248197)
47. Chen XD, Fisher LW, Robey PG, &, Young MF, (2004) The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J 18, 948-958. (Pubitemid 38787591)
48. Mochida Y, Parisuthiman D, &, Yamauchi M, (2006) Biglycan is a positive modulator of BMP-2 induced osteoblast differentiation. Adv Exp Med Biol 585, 101-113.
49. Desnoyers L, Arnott D, &, Pennica D, (2001) WISP-1 binds to decorin and biglycan. J Biol Chem 276, 47599-47607.
50. Schaefer L, &, Iozzo RV, (2008) Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 283, 21305-21309.
51. Merline R, Schaefer RM, &, Schaefer L, (2009) The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal 3, 323-335.
52. Iozzo RV, &, Schaefer L, (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277, 3864-3875.
53. Schaefer L, (2011) Small leucine-rich proteoglycans in kidney disease. J Am Soc Nephrol 22, 1200-1207.
54. Brandan E, Cabello-Verrugio C, &, Vial C, (2008) Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol 27, 700-708.
55. Little PJ, Osman N, &, O'Brien KD, (2008) Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol 19, 448-454.
56. Young MF, &, Fallon JR, (2012) Biglycan: a promising new therapeutic for neuromuscular and musculoskeletal diseases. Curr Opin Genet Dev 22, 398-400.
57. Merline R, Nastase MV, Iozzo RV, &, Schaefer L, (2012) Small leucine-rich proteoglycans: multifunctional signaling effectors. In Extracellular Matrix: Pathobiology and Signaling (, Karamanos NK, ed.), pp. 185-196. Walter de Gruyter, Berlin/Boston.
58. Nastase MV, Young MF, &, Schaefer L, (2012) Biglycan: a multivalent proteoglycan providing structure and signals. J Histochem Cytochem 60, 963-975.
59. Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, Bruckner P, Pfeilschifter J, Schaefer RM, Grone HJ, et al,. (2009) Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem 284, 24035-24048.
60. Moreth K, Brodbeck R, Babelova A, Gretz N, Spieker T, Zeng-Brouwers J, Pfeilschifter J, Young MF, Schaefer RM, &, Schaefer L, (2010) The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest 120, 4251-4272.
61. Song R, Zeng Q, Ao L, Yu JA, Cleveland JC, Zhao KS, Fullerton DA, &, Meng X, (2012) Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via Toll-like receptor-2. Arterioscler Thromb Vasc Biol 32, 2711-2720.
62. Lamkanfi M, &, Dixit VM, (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28, 137-161.
63. Popovic ZV, Wang S, Papatriantafyllou M, Kaya Z, Porubsky S, Meisner M, Bonrouhi M, Burgdorf S, Young MF, Schaefer L, et al,. (2011) The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis. J Immunol 187, 6217-6226.
64. Adapala VJ, Ward M, &, Ajuwon K, (2012) Adipose tissue biglycan as a potential antiinflammatory target of sodium salicylate in mice fed a high fat diet. J Inflamm (Lond) 9, 15.
65. Kikuchi A, Tomoyasu H, Kido I, Takahashi K, Tanaka A, Nonaka I, Iwakami N, &, Kamo I, (2000) Haemopoietic biglycan produced by brain cells stimulates growth of microglial cells. J Neuroimmunol 106, 78-86. (Pubitemid 30256080)
66. Sjoberg AP, Manderson GA, Morgelin M, Day AJ, Heinegard D, &, Blom AM, (2009) Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol 46, 830-839.
67. Kitaya K, &, Yasuo T, (2009) Dermatan sulfate proteoglycan biglycan as a potential selectin L/CD44 ligand involved in selective recruitment of peripheral blood CD16(-) natural killer cells into human endometrium. J Leukoc Biol 85, 391-400.
68. Reed CC, &, Iozzo RV, (2002) The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 19, 249-255. (Pubitemid 37174552)
69. Seidler DG, (2012) The galactosaminoglycan-containing decorin and its impact on diseases. Curr Opin Struct Biol 22, 578-582.
70. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, &, Iozzo RV, (1997) Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 136, 729-743. (Pubitemid 27083772)
71. Zhang G, Ezura Y, Chervoneva I, Robinson PS, Beason DP, Carine ET, Soslowsky LJ, Iozzo RV, &, Birk DE, (2006) Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J Cell Biochem 98, 1436-1449. (Pubitemid 44141849)
72. Ferdous Z, Lazaro LD, Iozzo RV, Hook M, &, Grande-Allen KJ, (2008) Influence of cyclic strain and decorin deficiency on 3D cellularized collagen matrices. Biomaterials 29, 2740-2748.
73. Iozzo RV, Moscatello DK, McQuillan DJ, &, Eichstetter I, (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274, 4489-4492.
74. Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, &, Iozzo RV, (1998) Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101, 406-412. (Pubitemid 28067338)
75. Neill T, Schaefer L, &, Iozzo RV, (2012) Decorin: a guardian from the matrix. Am J Pathol 181, 380-387.
76. Schonherr E, Sunderkotter C, Iozzo RV, &, Schaefer L, (2005) Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 280, 15767-15772. (Pubitemid 40616696)
77. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Grone HJ, Reinhardt DP, Pfeilschifter J, Iozzo RV, et al,. (2007) Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin. Am J Pathol 170, 301-315. (Pubitemid 47339209)
78. Merline R, Lazaroski S, Babelova A, Tsalastra-Greul W, Pfeilschifter J, Schluter KD, Gunther A, Iozzo RV, Schaefer RM, &, Schaefer L, (2009) Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol 60 (Suppl 4), 5-13.
79. Iozzo RV, Buraschi S, Genua M, Xu SQ, Solomides CC, Peiper SC, Gomella LG, Owens RC, &, Morrione A, (2011) Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 286, 34712-34721.
80. Goldoni S, Humphries A, Nystrom A, Sattar S, Owens RT, McQuillan DJ, Ireton K, &, Iozzo RV, (2009) Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 185, 743-754.
81. Khan GA, Girish GV, Lala N, Di Guglielmo GM, &, Lala PK, (2011) Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast. Mol Endocrinol 25, 1431-1443.
82. Brandan E, Retamal C, Cabello-Verrugio C, &, Marzolo MP, (2006) The low density lipoprotein receptor-related protein functions as an endocytic receptor for decorin. J Biol Chem 281, 31562-31571. (Pubitemid 46041422)
83. Iozzo RV, &, Sanderson RD, (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15, 1013-1031.
84. Schaefer L, Macakova K, Raslik I, Micegova M, Grone HJ, Schonherr E, Robenek H, Echtermeyer FG, Grassel S, Bruckner P, et al,. (2002) Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 160, 1181-1191. (Pubitemid 34224603)
85. Goldoni S, &, Iozzo RV, (2008) Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123, 2473-2479.
86. Theocharis AD, Skandalis SS, Tzanakakis GN, &, Karamanos NK, (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 3904-3923.
87. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, &, Ruoslahti E, (1992) Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360, 361-364. (Pubitemid 23000677)
88. Williams KJ, Qiu G, Usui HK, Dunn SR, McCue P, Bottinger E, Iozzo RV, &, Sharma K, (2007) Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol 171, 1441-1450. (Pubitemid 350158306)
89. Kolb M, Margetts PJ, Sime PJ, &, Gauldie J, (2001) Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 280, L1327-L1334.
90. Weis SM, Zimmerman SD, Shah M, Covell JW, Omens JH, Ross J Jr, Dalton N, Jones Y, Reed CC, Iozzo RV, et al,. (2005) A role for decorin in the remodeling of myocardial infarction. Matrix Biol 24, 313-324. (Pubitemid 40853880)
91. Baghy K, Iozzo RV, &, Kovalszky I, (2012) Decorin-TGFbeta axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem 60, 262-268.
92. Yamaguchi Y, Mann DM, &, Ruoslahti E, (1990) Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346, 281-284.
93. Baghy K, Dezso K, Laszlo V, Fullar A, Peterfia B, Paku S, Nagy P, Schaff Z, Iozzo RV, &, Kovalszky I, (2011) Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest 91, 439-451.
94. Vial C, Gutierrez J, Santander C, Cabrera D, &, Brandan E, (2011) Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity. J Biol Chem 286, 24242-24252.
95. Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, &, Eichstetter I, (1999) Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA 96, 3092-3097. (Pubitemid 29148849)
96. Santra M, Reed CC, &, Iozzo RV, (2002) Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope. J Biol Chem 277, 35671-35681.
97. Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnoczky G, &, Iozzo RV, (2000) Sustained down-regulation of the epidermal growth factor receptor by decorin: a mechanism for controlling tumor growth in vivo. J Biol Chem 275, 32879-32887.
98. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RT, McQuillan DJ, &, Iozzo RV, (2006) Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281, 26408-26418. (Pubitemid 44401849)
99. Neill T, Painter H, Buraschi S, Owens RT, Lisanti MP, Schaefer L, &, Iozzo RV, (2012) Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1alpha, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J Biol Chem 287, 5492-5506.
100. Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T, &, Iozzo RV, (2010) Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels. J Biol Chem 285, 42075-42085.
101. Buraschi S, Neill T, Owens RT, Iniguez LA, Purkins G, Vadigepalli R, Evans B, Schaefer L, Peiper SC, Wang ZX, et al,. (2012) Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PLoS ONE 7, e45559.
102. Sofeu Feugaing DD, Gotte M, &, Viola M, (2013) More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol 92, 1-11.
103. Seidler DG, Mohamed NA, Bocian C, Stadtmann A, Hermann S, Schafers K, Schafers M, Iozzo RV, Zarbock A, &, Gotte M, (2011) The role for decorin in delayed-type hypersensitivity. J Immunol 187, 6108-6119.
104. Onuma H, Tabara Y, Kawamura R, Ohashi J, Nishida W, Takata Y, Ochi M, Nishimiya T, Kawamoto R, Kohara K, et al,. (2012) Plasma resistin is associated with single nucleotide polymorphisms of a possible resistin receptor, the decorin gene, in the general Japanese population. Diabetes 62, 649-652.
105. Benomar Y, Gertler A, De Lacy P, Crepin D, Hamouda HO, Riffault L, &, Taouis M, (2012) Central resistin overexposure induces insulin resistance through Toll-like receptor 4. Diabetes 62, 102-114.
106. Kolb M, Margetts PJ, Galt T, Sime PJ, Xing Z, Schmidt M, &, Gauldie J, (2001) Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med 163, 770-777. (Pubitemid 32230842)
107. Wu B, Huan T, Gong J, Zhou P, &, Bai Z, (2011) Domain combination of the vertebrate-like TLR gene family: implications for their origin and evolution. J Genet 90, 401-408.
108. Inohara N, Chamaillard M, McDonald C, &, Nunez G, (2005) NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 74, 355-383. (Pubitemid 40995511)
109. Vij N, Roberts L, Joyce S, &, Chakravarti S, (2005) Lumican regulates corneal inflammatory responses by modulating Fas-Fas ligand signaling. Invest Ophthalmol Vis Sci 46, 88-95. (Pubitemid 40041183)
110. Carlson EC, Lin M, Liu CY, Kao WW, Perez VL, &, Pearlman E, (2007) Keratocan and lumican regulate neutrophil infiltration and corneal clarity in lipopolysaccharide-induced keratitis by direct interaction with CXCL1. J Biol Chem 282, 35502-35509. (Pubitemid 350277127)
111. Hayashi Y, Call MK, Chikama T, Liu H, Carlson EC, Sun Y, Pearlman E, Funderburgh JL, Babcock G, Liu CY, et al,. (2010) Lumican is required for neutrophil extravasation following corneal injury and wound healing. J Cell Sci 123, 2987-2995.
112. Lohr K, Sardana H, Lee S, Wu F, Huso DL, Hamad AR, &, Chakravarti S, (2012) Extracellular matrix protein lumican regulates inflammation in a mouse model of colitis. Inflamm Bowel Dis 18, 143-151.
113. Wu F, Vij N, Roberts L, Lopez-Briones S, Joyce S, &, Chakravarti S, (2007) A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. J Biol Chem 282, 26409-26417. (Pubitemid 47443780)
114. -/- mice show increased pseudomonas aeruginosa lung infection severity. J Biol Chem 287, 35860-35872.
115. Potter-Perigo S, Johnson PY, Evanko SP, Chan CK, Braun KR, Wilkinson TS, Altman LC, &, Wight TN, (2010) Polyinosine-polycytidylic acid stimulates versican accumulation in the extracellular matrix promoting monocyte adhesion. Am J Respir Cell Mol Biol 43, 109-120.
116. Wang W, Xu GL, Jia WD, Ma JL, Li JS, Ge YS, Ren WH, Yu JH, &, Liu WB, (2009) Ligation of TLR2 by versican: a link between inflammation and metastasis. Arch Med Res 40, 321-323.
117. Zhang Z, Miao L, &, Wang L, (2012) Inflammation amplification by versican: the first mediator. Int J Mol Sci 13, 6873-6882.
118. Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT, &, Wight TN, (2012) Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol 31, 90-100.
119. Chang MY, Chan CK, Braun KR, Green PS, O'Brien KD, Chait A, Day AJ, &, Wight TN, (2012) Monocyte-to-macrophage differentiation: synthesis and secretion of a complex extracellular matrix. J Biol Chem 287, 14122-14135.
120. Said N, Sanchez-Carbayo M, Smith SC, &, Theodorescu D, (2012) RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest 122, 1503-1518.
121. Iozzo RV, &, Murdoch AD, (1996) Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 10, 598-614. (Pubitemid 26141171)
122. Wu YJ, La Pierre DP, Wu J, Yee AJ, &, Yang BB, (2005) The interaction of versican with its binding partners. Cell Res 15, 483-494. (Pubitemid 41653919)
123. Wight TN, (2008) Arterial remodeling in vascular disease: a key role for hyaluronan and versican. Front Biosci 13, 4933-4937. (Pubitemid 351599647)
124. Rutnam ZJ, Wight TN, &, Yang BB, (2012) miRNAs regulate expression and function of extracellular matrix molecules. Matrix Biol, doi: 10.1016/jmatbio.2012.11.003.
125. Ween MP, Oehler MK, &, Ricciardelli C, (2011) Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 12, 1009-1029.
126. Wight TN, (2012) The pathobiology of versican. In Extracellular Matrix: Pathobiology and Signaling (, Karamanos NK, ed.), pp. 154-170. Walter de Gruyter, Berlin/Boston.
127. Wight TN, (2002) Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 14, 617-623. (Pubitemid 35247746)
128. Toeda K, Nakamura K, Hirohata S, Hatipoglu OF, Demircan K, Yamawaki H, Ogawa H, Kusachi S, Shiratori Y, &, Ninomiya Y, (2005) Versican is induced in infiltrating monocytes in myocardial infarction. Mol Cell Biochem 280, 47-56. (Pubitemid 41829799)
129. Wingrove JA, Daniels SE, Sehnert AJ, Tingley W, Elashoff MR, Rosenberg S, Buellesfeld L, Grube E, Newby LK, Ginsburg GS, et al,. (2008) Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet 1, 31-38.
130. Lang R, Patel D, Morris JJ, Rutschman RL, &, Murray PJ, (2002) Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 169, 2253-2263. (Pubitemid 34920965)
131. Asplund A, Friden V, Stillemark-Billton P, Camejo G, &, Bondjers G, (2011) Macrophages exposed to hypoxia secrete proteoglycans for which LDL has higher affinity. Atherosclerosis 215, 77-81.
132. Hynes RO, (2009) The extracellular matrix: not just pretty fibrils. Science 326, 1216-1219.
133. Hascall VC, Majors AK, De La Motte CA, Evanko SP, Wang A, Drazba JA, Strong SA, &, Wight TN, (2004) Intracellular hyaluronan: a new frontier for inflammation? Biochim Biophys Acta 1673, 3-12. (Pubitemid 38844790)
134. De La Motte CA, Hascall VC, Calabro A, Yen-Lieberman B, &, Strong SA, (1999) Mononuclear leukocytes preferentially bind via CD44 to hyaluronan on human intestinal mucosal smooth muscle cells after virus infection or treatment with poly(IC). J Biol Chem 274, 30747-30755.
135. Kawashima H, Hirose M, Hirose J, Nagakubo D, Plaas AH, &, Miyasaka M, (2000) Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J Biol Chem 275, 35448-35456.
136. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, et al,. (2005) Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11, 1173-1179. (Pubitemid 43093664)
137. Jiang D, Liang J, &, Noble PW, (2007) Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 23, 435-461.
138. Jiang D, Liang J, &, Noble PW, (2011) Hyaluronan as an immune regulator in human diseases. Physiol Rev 91, 221-264.
139. Kouvidi K, Berdiaki A, Nikitovic D, Katonis P, Afratis N, Hascall VC, Karamanos NK, &, Tzanakakis GN, (2011) Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. J Biol Chem 286, 38509-38520.
140. Hascall V, &, Esko JD, (2009) Hyaluronan. In Essentials of Glycobiology (2nd edition) (, Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, &, Etzler ME, eds), pp. 219-228. Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY).
141. Hascall V, &, Karamanos N, (2011) Regulatory roles of hyaluronan in health and disease. FEBS J 278, 1411.
142. Wang A, De la Motte C, Lauer M, &, Hascall V, (2011) Hyaluronan matrices in pathobiological processes. FEBS J 278, 1412-1418.
143. Oikari SJT, Tammi RH, &, Tammi MI, (2012) Multiple roles of hyaluronan as a target and modifier of the inflammatory response. In Extracellular Matrix: Pathobiology and Signaling (, Karamanos NK, ed.), pp. 39-65. Walter de Gruyter, Berlin/Boston.
144. De la Motte CA, (2011) Hyaluronan in intestinal homeostasis and inflammation: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 301, G945-G949.
145. Hill DR, Kessler SP, Rho HK, Cowman MK, &, De la Motte CA, (2012) Specific-sized hyaluronan fragments promote expression of human beta-defensin 2 in intestinal epithelium. J Biol Chem 287, 30610-30624.
146. Liu YY, Lee CH, Dedaj R, Zhao H, Mrabat H, Sheidlin A, Syrkina O, Huang PM, Garg HG, Hales CA, et al,. (2008) High-molecular-weight hyaluronan-a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats. Crit Care 12, R102.
147. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, &, Horton MR, (2006) Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 177, 1272-1281. (Pubitemid 44036633)
148. Heldin P, Karousou E, Bernert B, Porsch H, Nishitsuka K, &, Skandalis SS, (2008) Importance of hyaluronan-CD44 interactions in inflammation and tumorigenesis. Connect Tissue Res 49, 215-218.
149. Wuthrich RP, (1999) The proinflammatory role of hyaluronan-CD44 interactions in renal injury. Nephrol Dial Transplant 14, 2554-2556. (Pubitemid 32208356)
150. Collins SL, Black KE, Chan-Li Y, Ahn YH, Cole PA, Powell JD, &, Horton MR, (2011) Hyaluronan fragments promote inflammation by down-regulating the anti-inflammatory A2a receptor. Am J Respir Cell Mol Biol 45, 675-683.
151. Taylor KR, Yamasaki K, Radek KA, Di Nardo A, Goodarzi H, Golenbock D, Beutler B, &, Gallo RL, (2007) Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 282, 18265-18275. (Pubitemid 47100227)
152. Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, Bertin J, Grant EP, Coyle AJ, Misaghi A, Hoffman HM, et al,. (2009) NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 284, 12762-12771.
153. Del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon MC, Soler-Ranger L, Fuentes-Prior P, Escoll P, Baos R, Caveda L, Garcia F, et al,. (2005) Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 174, 3032-3040. (Pubitemid 40279724)
154. Bollyky PL, Lord JD, Masewicz SA, Evanko SP, Buckner JH, Wight TN, &, Nepom GT, (2007) Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells. J Immunol 179, 744-747.
155. Bollyky PL, Wu RP, Falk BA, Lord JD, Long SA, Preisinger A, Teng B, Holt GE, Standifer NE, Braun KR, et al,. (2011) ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci USA 108, 7938-7943.
156. Day AJ, &, De la Motte CA, (2005) Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol 26, 637-643. (Pubitemid 41628196)